Additionally, we examined the clinicopathological features, microsatellite instability (MSI) status, tumor mutation burden (TMB), CpG island methylator phenotype (CIMP), BRAF classification, and the clinicopathological and molecular differences between CRCs with single KRAS or BRAF mutations and those with double mutations. Here, KRAS is linked to neoplasm.